Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPRG | P23470 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499583 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL48235 | 0.85 | MAPT (0.52) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL5682647 | 0.82 | MAPT (0.50) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL499641 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL17755 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL30482609 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL2637828 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL29740498 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL1457582 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBHPGDLMNA | |
| SCHEMBL499767 | 0.80 | MAPT (0.67) | ALDH1A1MAPTPOLBHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 641/4885MAPT 1540/4885POLB 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.